616
Participants
Start Date
September 30, 2010
Primary Completion Date
October 31, 2013
Study Completion Date
October 31, 2013
Omalizumab
The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
Placebo
The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Beijing
Novartis Investigative Site, Shengyang
Novartis Investigative Site, Changchun
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Shanghai
Novartis Investigative Site, Suzhou
Novartis Investigative Site, Suzhou
Novartis Investigative Site, Hangzhou
Novartis Investigative Site, Nanchang
Novartis Investigative Site, Chongqing
Novartis Investigative Site, Chongqing
Novartis Investigative Site, Chongqing
Novartis Investigative Site, Changsha
Novartis Investigative Site, Changsha
Novartis Investigative Site, Changsha
Novartis Investigative Site, Wuhan
Novartis Investigative Site, Wuhan
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Guangzhou
Novartis Investigative Site, Nanning
Novartis Investigative Site, Chengdu
Novartis Investigative Site, Xian
Novartis Investigative Site, Xi’an
Novartis Investigative Site, Xi’an
Novartis Investigative Site, Beijing
Novartis Investigative Site, Nanjing
Novartis Investigative Site, Shenyang
Novartis Investigative Site, Beijing
Novartis Investigative Site, Nanjing
Novartis Investigative Site, Shijiazhuang
Lead Sponsor
Collaborators (1)
Genentech, Inc.
INDUSTRY
Novartis Pharmaceuticals
INDUSTRY